Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes mellitus and obesity : the impact of pharmacological properties and genetic factors
ID
Klen, Jasna
(
Author
),
ID
Dolžan, Vita
(
Author
)
PDF - Presentation file,
Download
(1,07 MB)
MD5: 5839972C4AD480CC01A2207D455282D1
URL - Source URL, Visit
https://www.mdpi.com/1422-0067/23/7/3451
Image galllery
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of antihyperglycemic drugs that enhance appropriate pancreatic β-cell secretion, pancreatic α-cell (glucagon) suppression, decrease liver glucose production, increase satiety through their action on the central nervous system, slow gastric emptying time, and increase insulin action on peripheral tissue. They are effective in the management of type 2 diabetes mellitus and have a favorable effect on weight loss. Their cardiovascular and renal safety has been extensively investigated and confirmed in many clinical trials. Recently, evidence has shown that in addition to the existing approaches for the treatment of obesity, semaglutide in higher doses promotes weight loss and can be used as a drug to treat obesity. However, some T2DM and obese patients do not achieve a desired therapeutic effect of GLP-1 receptor agonists. This could be due to the multifactorial etiologies of T2DM and obesity, but genetic variability in the GLP-1 receptor or signaling pathways also needs to be considered in non-responders to GLP-1 receptor agonists. This review focuses on the pharmacological, clinical, and genetic factors that may influence the response to GLP-1 receptor agonists in the treatment of type 2 diabetes mellitus and obesity.
Language:
English
Keywords:
type 2 diabetes mellitus
,
obesity
,
GLP‐1 receptor agonists
,
incretins
,
cardiovascular safety
,
genetic polymorphisms
Work type:
Article
Typology:
1.02 - Review Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2022
Number of pages:
18 str.
Numbering:
Vol. 23, iss. 7, art. 3451
PID:
20.500.12556/RUL-137512
UDC:
616.379
ISSN on article:
1422-0067
DOI:
10.3390/ijms23073451
COBISS.SI-ID:
101977091
Publication date in RUL:
20.06.2022
Views:
655
Downloads:
166
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
International journal of molecular sciences
Shortened title:
Int. j. mol. sci.
Publisher:
MDPI
ISSN:
1422-0067
COBISS.SI-ID:
2779162
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:
01.04.2022
Secondary language
Language:
Slovenian
Keywords:
diabetes mellitus tipa 2
,
debelost
,
agonisti receptorjev GLP-1
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0170
Name:
Molekulski mehanizmi uravnavanja celičnih procesov v povezavi z nekaterimi boleznimi pri človeku
Funder:
ARRS - Slovenian Research Agency
Project number:
P3-0298
Name:
Geni, hormonske in osebnostne spremembe pri metabolnih motnjah
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back